Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE S2 ( May, 2021 ) > List of Articles


Melioidosis in Critical Care: A Review

Sowmya Sridharan, Isabella B Princess

Citation Information :

DOI: 10.5005/jp-journals-10071-23837

License: CC BY-NC 4.0

Published Online: 01-05-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Key Points: (1) Diabetes, hazardous alcohol use, and/or significant heart disease are more likely to develop a critical illness with melioidosis. (2) Pneumonia is the most common presentation. Those with pneumonia or bacteremia are most likely to require intensive care unit admissions. (3) Culture is the mainstay for the diagnosis. However, it is noted that Burkholderia pseudomallei is often wrongly identified as Pseudomonas or other Burkholderia species by commonly available commercial techniques. (4) Therapy consists of an intensive phase with intravenous antibiotics to prevent mortality followed by an eradication phase with oral antibiotics to prevent relapse. (5) Meropenem is the drug of choice for those with septic shock or neurological involvement. For patients with nonpulmonary organ focal sites of infection (neurologic, prostatic, bone, joint, cutaneous, and soft tissue melioidosis), the addition of trimethoprim-sulfamethoxazole (TMP-SMX) to ceftazidime/carbapenem during intensive therapy is recommended. TMP-SMX is the drug of choice for oral antibiotic therapy during the eradication phase. (6) Adequate source control is essential for successful treatment and to prevent relapse. (7) The use of granulocyte-colony stimulating factor (G-CSF) those with septic shock is controversial.

  1. Dance DAB. Ecology of Burkholderia pseudomallei and the interactions between environmental Burkholderia spp. and human–animal hosts. Acta Trop 2000;74(2–3):159–168. DOI: 10.1016/s0001-706x(99)00066-2.
  2. Stephens DP, Thomas JH, Ward LM, et al. Melioidosis causing critical illness. Crit Care Med 2016;44(8):1500–1505. DOI: 10.1097/ccm.0000000000001668.
  3. Chakravorty A, Heath CH. Melioidosis: an updated review. Aust J Gen Pract 2019;48:327–332. DOI: 10.31128/ajgp-04-18-4558.
  4. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005;18(2):383–416. Available at:
  5. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999;29(2):408–413. DOI: 10.1086/520223.
  6. Currie BJ, Fisher DA, Anstey NM, et al. Melioidosis: acute and chronic disease, relapse and re-activation. Trans R Soc Trop Med Hyg 2000;94(3):301–304. DOI: 10.1016/s0035-9203(00)90333-x.
  7. Currie BJ, Ward L, Cheng AC. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 2010;4(11):e900. Available at:
  8. McLeod C, Morris PS, Bauert PA, et al. Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the northern territory of Australia and review of the literature. Clin Infect Dis 2014;60(1):21–26. DOI: 10.1093/cid/ciu733.
  9. Princess I, Ebenezer R, Ramakrishnan N, et al. Melioidosis: an emerging infection with fatal outcomes. Indian J Crit Care Med 2017;21(6):397–400. Available at:
  10. Lau SKP, Sridhar S, Ho C-C, et al. Laboratory diagnosis of melioidosis: past, present and future. Exp Biol Med 2015;240(6):742–751. Available at:
  11. Dance DA, Wuthiekanun V, Naigowit P, et al. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol 1989;42(6):645–648. Available at:
  12. Meumann EM, Cheng AC, Ward L, et al. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin Infect Dis 2012;54(3):362–369. Available at:
  13. Currie BJ, Fisher DA, Howard DM, et al. Neurological melioidosis. Acta Trop 2000;74(2–3):145–151. DOI: 10.1016/s0001-706x(99)00064-9.
  14. White NJ, Chaowagul W, Wuthiekanun V, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989;334(8665):697–701. DOI: 10.1016/s0140-6736(89)90768-x.
  15. Sookpranee M, Boonma P, Susaengrat W, et al. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992;36(1):158–162. Available at:
  16. Simpson AJH, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999;29(2):381–387. DOI: 10.1086/520219.
  17. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004;48(5):1763–1765. Available from:
  18. Sullivan RP, Marshall CS, Anstey NM, et al. 2020 review and revision of the 2015 Darwin melioidosis treatment guideline; paradigm drift not shift. PLoS Negl Trop Dis 2020;14(9):e0008659. Available at:
  19. Chetchotisakd P, Chierakul W, Chaowagul W, et al. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet 2014;383(9919):807–814. Available at:
  20. Cheng AC, Stephens DP, Anstey NM, et al. Adjunctive granulocyte colony‐stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004;38(1):32–37. DOI: 10.1086/380456.
  21. Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007;45(3):308–314. DOI: 10.1086/519261.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.